

Color PMS Black

EN-3406

EN-3406 NITROPRESS[®] (Sodium Nitroprusside Injection)

Fliptop Vial

Rx only

_ _ _ _ _

_ _ _ _ _

Rx only

Hospira, Inc., Lake Forest, IL 60045 USA



Revised: 12/2013

To protect NITROPRESS from light, it should be stored in its carton until it is used.

(NDC 0409-3024-01) Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Store at 20 to 25°C (68 to 77°F).

VIDS 2000 2001 (Section) is supplied in amber-colored, single-dose 50 mg/2 mL Fliptop Vials **ΔΞΙΤΔΔΛΙΣ ΜΟΗ**

WARKING: Uo not use tlexible container in series connections.

tested for these toxicities.

10 mg/kg of sodium nitroprusside will develop methemoglobinemis, other patients, especially those with impaired renal function, will predictably develop thiocyanate toxicity after prolonged, rapid infusions. In secondance with the descriptions in **ADVERSE REACTIONS** above, patients with suggestive findings should be tested for these provinies sodium thiosulfate as this may result in thiocyanate toxicity and hypovolemia. Incentious administration of sodium nitropusated must still be evoided, and all of the preceding concerning sodium nitroprusside administration must still be observed. Consideration of methemoglobinemia and thiocyanate (straty: faste patients receiving there the

Co-intusions of sodium thiozothete have been administered at rates of 5-10 times that of sodium nitroprusside. The must be taken to avoid the indistriminate use of prolonged or high deses of taken to avoid the indistriminate

recommended without reservation. In one study, sodium thiosulfate appeared to potentiate the hypotensive effects of sodium nitroprusside.

Rou macykg of sodium nitroprusatia is administeriate basater than 2 mag/kg nitro, cyanida is apreviate faster that a mag/kg nitroprusatia is abravent to increase the rate the unaided patient so increase the rate the rate of cyanide processing, reducing the function of sodium situation of sodium situation of sodium situation of the rate of the rate processing reducing the rate of cyanide processing. For example, the rate of nent erom nerve, evode **Y20103AMAAHA 1A3INI13** ni bediraseb zA :**viicity:** bonde to somebiovA

1200	36	009	81	300	6	520	100
080 L	32	040	91	570	8	861	06
096	57	480	14	540	L	921	08
048	52	450	13	210	9	154	02
720	52	360	11	081	G	135	09
009	81	300	6	0G L	G	011	09
480	14	240	L	120	t	88	01/2
390	11	081	G	06	3	99	30
240	L	150	4	09	5	44	50
150	4	09	2	30	l	52	01
хвт	tini	xem	tini	хеш	tini	tdpiaw Ibs	64 1d
20 աcð/աך քն ամ		ן00 שכ6/שך 20 ש6		500 աcâ\աך 20 աâ		Concentration Concentration	
Jm 0001		7W 00G		250 mL		Volume	

bns (nim/g/kgam 6.0) lisiul evshica (nitial (g/mcg/kg/min) and SE3A90ATIN of nog/kg/min) losing of NTTA90ATIN

hypopertusion. Table 2 below store infusion rates corresponding to the recommended initial and maximal doses (0.3 mcg/kg/min and 10 mcg/kg/min, respectively) for both adult and pediatric patients of various weights. This infusion rate may be lower than indicated in the table for patients less than 10 kg. Note that when the concentration used in a given patient is changed, the tubing is still filled with a solution at the previous concentration.

ventricular filling pressure must not be purchased at the price of undue hypotension and consequent systemic blood pressure cannot be further reduced without compromising the perfusion of vital organs, or
 the maximum recommended infusion rate has been reached, whichever comes earliest. Specific the modynamic goals must be tailored to the clinical situation, but improvements in cardiac output and left the modynamic goals.

rate must be guided by the results of invasive hemodynamic monitoring with simultaneous monitoring of urine output. Sodium nitroprusside can be titrated by increasing the infusion rate until: • measured cardiac output is no longer increasing.

or a patient receiving this drug must be continuously monitored, using either a continually reinflated sphygmomanometer or (preferably) an intra-arterial pressure sensor. Special caution should be used in elderly patients, since they may be more sensitive to the hypotensive effects of the drug. When sould my intra-side is used in the treatment of acute congestive heat failure, thration of the invisor.

through ordinary I.V. apparatus, regulated only by gravity and mechanical clamps. Only an infusion pump, preferably a volumetric pump, should be used. Because sodium nitroprusside can induce essentially unlimited blood-pressure reduction, the blood pressure in infusion rate can lead to wide, undesirable variations in blood pressure. Since there is inherent variation in blood pressure measurement, confirm the drug effect at any infusion rate after an additional 5 minutes before brating to a higher dose to achieve the desired blood pressure. Sodium nitroprusside should not be infused

Because sodium nitroprusside's hypotensive effect is very rapid in onset and in dissipation, small variations Infusion of sodium nitroprusside should therefore be started at a very low rate (0,5 mcg/kg/mc), with the atom to the solid therefore be started at a very low rate (1,0,0,mc) (kg/mc) atom rate (1,0,mc)(kg/mc) atom rate (1,0,mc)(kg/mc) atom rate (1,0,mc)(kg/mc) atom rate (1,0,mc)(kg/mc) atom rate (1,0,mc) atom rate (

huoda si stnaŭsci cinstrante protective internation de la service internation de la service internation de la s Biogly physical en al service international de la service and an al service international de la service service Biogly physical en al service international de la service and an al service international de la service international tuode si stneitea No other drugs should be administered in the same solution with sodium nitroprusside.


NITROPRESS® (Sodium Nitroprusside Injection) is not suitable for direct injection. The solution must be further diluted in sterile 5% dextrose injection before infusion. NITROPRESS can cause precipitous decreases in blood pressure (see DOSAGE AND ADMINISTRATION). In patients not properly monitored, these decreases can lead to irreversible ischemic injuries or death. Sodium nitroprusside should be used only when available equipment and personnel allow blood pressure to be continuously monitored. Except when used briefly or at low (< 2 mcg/kg/min) infusion rates, sodium nitroprusside gives rise to important quantities of cyanide ion, which can reach toxic, potentially lethal levels (see WARNINGS). The usual dose rate is 0.5-10 mcg/kg/min, but infusion at the maximum dose rate should never last more than 10 minutes. If blood pressure has not been adequately controlled after 10 minutes of infusion at the maximum rate, administration of sodium nitroprussides hould be used be monitored and may indicate cyanide toxicity, these laboratory tests provide imperfect guidance.

NITROPRESS[®] (Sodium Nitroprusside Injection)

DESCRIPTION

Fliptop Vial

Sodium nitroprusside is disodium pentacyanonitrosylferrate(2-) dihydrate, a hypotensive agent whose structural formula is



 $\label{eq:solution} Sodium Nitroprusside $$ whose molecular formula is Na2[Fe(CN)5N0] \bullet 2H_20, and whose molecular weight is 297.95. Dry sodium nitroprusside is a reddish-brown powder, soluble in water. In an aqueous solution infused intravenously, sodium $$ Na2[Fe(CN)5N0] \bullet 2H_20, and $$ whose molecular weight is 297.95. The solution infused intravenously solution infused intravenously. The solution infused intravenously is the solution infused intravenously. The solution infused intravenously is the solution infused intravenously. The solution infused intravenously is the solution infused intravenously. The solution infused intravenously is the solution infused intravenously. The solution infused intravenously is the solution infused intravenously. The solution infused intravenously is the solution infused intravenously. The solution infused intravenously is the solution infused intravenously. The solution infused intravenously is the solution infused intravenously. The solution infused intravenously is the solution infused intravenously is the solution infused intravenously. The solution infused intravenously is the solution infused intravenously is the solution infused intravenously is the solution infused intravenously. The solution infused intravenously is the solution information information information information information information information informa$

nitroprusside is a rapid-acting vasodilator, active on both arteries and veins. Sodium nitroprusside solution is rapidly degraded by trace contaminants, often with resulting color changes. (See **DOSAGE AND ADMINISTRATION** section.) The solution is also sensitive to certain wavelengths of light,

and it must be protected from light in clinical use. NITROPRESS (Sodium Nitroprusside Injection) is available as: 50 mg Fliptop Vial – Each 2 mL vial contains the equivalent of 50 mg sodium nitroprusside dihydrate in sterile water for injection.

CLINICAL PHARMACOLOGY

The principal pharmacological action of sodium nitroprusside is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins. Other smooth muscle (*e.g.*, uterus, duodenum) is not affected. Sodium nitroprusside is more active on veins than on arteries, but this selectivity is much less marked than that of nitroglycerin. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to the heart, thereby reducing left ventricular end diastolic pressure and pulmonary capillary wedge pressure (preload). Arteriolar relaxation reduces systemic vascular resistance, systolic arterial pressure, and mean arterial pressure (afterload). Dilatation of the coronary arteries also occurs. In association with the decrease in blood pressure, sodium nitroprusside administered intravenously to

hypertensive and normotensive patients produces slight increases in heart rate and a variable effect on cardiac output. In hypertensive patients, moderate doses induce renal vasodilatation roughly proportional to the decrease in systemic blood pressure, so there is no appreciable change in renal blood flow or glomerular filtration rate

In normotensive subjects, acute reduction of mean arterial pressure to 60-75 mm Hg by infusion of sodium nitroprusside caused a significant increase in renin activity. In the same study, ten renovascular-hypertensive patients given sodium nitroprusside had significant increases in renin release from the involved kidney at mean The hypotensive effect of sodium nitroprusside is seen within a minute or two after the start of an adequate

infusion, and it dissipates almost as rapidly after an infusion is discontinued. The effect is augmented by

ganglionic blocking agents and inhaled anesthetics. **Pharmacokinetics and Metabolism:** Infused sodium nitroprusside is rapidly distributed to a volume that is approximately coextensive with the extracellular space. The drug is cleared from this volume by intraerythrocytic reaction with hemoglobin (Hgb), and sodium nitroprusside's resulting circulatory half-life is about 2 minutes

The products of the nitroprusside/hemoglobin reaction are cyanmethemoglobin (cyanmetHgb) and cyanide ion (CN[¬]). Safe use of sodium nitroprusside injection must be guided by knowledge of the further metabolism of


these products. As shown in the diagram below, the essential features of nitroprusside metabolism are

• one molecule of sodium nitroprusside is metabolized by combination with hemoglobin to produce one molecule of cyanmethemoglobin and four CN⁻ ions;
methemoglobin, obtained from hemoglobin, can sequester cyanide as cyanmethemoglobin;
thiosulfate reacts with cyanide to produce thiocyanate;

 thiocvanate is eliminated in the urine: cyanide not otherwise removed binds to cytochromes; and

cyanide is much more toxic than methemoglobin or thiocyanate

Metabolism of Sodium Nitroprusside



Cyanide ion is normally found in serum; it is derived from dietary substrates and from tobacco smoke. Cyanide binds avidly (but reversibly) to ferric ion (Fe^{+++}), most body stores of which are found in erythrocyte methemoglobin (metHgb) and in mitochondrial cytochromes. When CN^- is infused or generated within the bloodstream, essentially all of it is bound to methemoglobin until intraerythrocytic methemoglobin has been saturated.

saturated. When the Fe⁺⁺⁺ of cytochromes is bound to cyanide, the cytochromes are unable to participate in oxidative metabolism. In this situation, cells may be able to provide for their energy needs by utilizing anaerobic pathways, but they thereby generate an increasing body burden of lactic acid. Other cells may be unable to utilize these alternative pathways, and they may die hypoxic deaths. CN⁻ levels in packed erythrocytes are typically less than 1 µmol/L (less than 25 mcg/L); levels are roughly deathed in back are the set of th

doubled in heavy smokers.

At healthy steady state, most people have less than 1% of their hemoglobin in the form of methemoglobin Nitroprusside metabolism can lead to methemoglobin formation (a) through dissociation of cyanmethemoglobin formation (a) through dissociation of cyanmethemoglobin formed in the original reaction of sodium nitroprusside with Hgb and (b) by direct oxidation of Hgb by the released nitroso group. Relatively large quantities of sodium nitroprusside, however, are required to produce At physiologic methemoglobin levels, the CN⁻ binding capacity of packed red cells is a little less than

At physiologic methemographic metric with a new physiologic metric can be a new response of a new resp

Some cyanide is eliminated from the body as expired hydrogen cyanide, but most is enzymatically converted to thiceyanate (SCN⁻) by thiosulfate-cyanide sulfur transferase (rhodanase, EC 2.8.1.1), a mitochondrial enzyme. The enzyme is normally present in great excess, so the reaction is rate-limited by the availability of sulfur donors, especially thiosulfate, cystine, and cysteine.

Thiosulfate is a normal constituent of serum, produced from cysteine by way of β -mercaptopyruvate. Physiological levels of thiosulfate are typically about 0.1 mmol/L (11 mg/L), but they are approximately twice this level in pediatric and adult patients who are not eating. Infused thiosulfate is cleared from the body (primarily by the kidneys) with a half-life of about 20 minutes.

by the kioneys) with a nari-life or about 20 minutes. When thisoulfate is being supplied only by normal physiologic mechanisms, conversion of CN⁻ to SCN⁻ generally proceeds at about 1 mcg/kg/min. This rate of CN⁻ clearance corresponds to steady-state processing of a sodium nitroprusside infusion of slightly more than 2 mcg/kg/min. CN⁻ begins to accumulate when sodium

nitroprusside infusions exceed this rate. Thiocyanate (SCN⁻) is also a normal physiological constituent of serum, with normal levels typically in the range of 50-250 µmol/L (3-15 mg/L). Clearance of SCN⁻ is primarily renal, with a half-life of about 3 days. In renal

range of 50-250 µmo/c (3-15 mg/c). Clearance of SCN is primarily renar, with a nan-life of about 3 days. In renar failure, the half-life can be doubled or tripled. **Clinical Trials:** Baseline-controlled clinical trials have uniformly shown that sodium nitroprusside has a prompt hypotensive effect, at least initially, in all populations. With increasing rates of infusion, sodium nitroprusside has been able to lower blood pressure without an observed limit of effect. Clinical trials have also shown that the hypotensive effect of sodium nitroprusside is associated with reduced blood loss in a variety of major surgical procedures. In patients with acute congestive heart failure and increased peripheral vascular resistance, administration of acdium eitropruscide acutors reductions in printser lesistance in acrease a output, and reductions

in left ventricular filling pressure. Many trials have verified the clinical significance of the metabolic pathways described above. In patients

receiving unopposed infusions of sodium nitroprusside, cyanide and thiocyanate levels have increased with increasing rates of sodium nitroprusside infusion. Mild to moderate metabolic acidosis has usually accompanied higher cyanide levels, but peak base deficits have lagged behind the peak cyanide levels by an hour or more.

Progressive tachyphylaxis to the hypotensive effects of sodium nitroprusside has been reported in several trials and numerous case reports. This tachyphylaxis has frequently been attributed to concomitant cyanide toxicity, but the only evidence adduced for this assertion has been the observation that in patients treated with sodium nitroprusside and found to be resistant to its hypotensive effects, cyanide levels are often found to be elevated. In the only reported *comparisons* of cyanide levels in resistant and nonresistant patients, cyanide levels did *not* correlate with tachyphylaxis. The mechanism of tachyphylaxis to sodium nitroprusside remains

Pediatric: The effects of sodium nitroprusside to induce hypotension were evaluated in two trials in pediatric patients less than 17 years of age. In both trials, at least 50% of the patients were pre-pubertal, and about 50% of these pre-pubertal patients were less than 2 years of age, including 4 neonates. The primary efficacy variable

of these pre-puberal patients were less than 2 years of age, including 4 heonates. The primary efficacy variable was the mean arterial pressure (MAP). There were 203 pediatric patients in a parallel, dose-ranging study (Study 1). During the 30 minute blinded phase, patients were randomized 1:1:1:1 to receive sodium nitroprusside 0.3, 1, 2, or 3 µg/kg/min. The infusion rate was increased step-wise to the target dose rate (i.e., 1/3 of the full rate for the first 5 minutes, 2/3 of the full rate for the next 5 minutes, and the full dose rate for the last 20 minutes). If the investigator believed that an increase to the next higher dose rate would be unsafe, the infusion remained at the current rate for the remainder form based from based fro remainder of the blinded infusion. Since there was no placebo group, the change from baseline likely overestimates the true magnitude of blood pressure effect. Nevertheless, MAP decreased 11 to 20 mmHg from

baseline across the four doses (Table 1). There were 63 pediatric patients in a long-term infusion trial (Study 2). During an open-label phase (12 to 24 hours), sodium nitroprusside was started at ≤0.3 µg/kg/min and titrated according to the BP response. Patients were then randomized to placebo or to continuing the same dose of sodium nitroprusside. The average MAP was greater in the control group than in the sodium nitroprusside group for every time point

ring the blinded withdrawal phase, demonstrating that sodium nitroprusside is effective for at least 12 hours. In both studies, similar effects on MAP were seen in all age groups.

Table 1: Change from Baseline in MAP (mmHg) After 30 Minutes Double-Blind Infusion (Stud	lv 1)
Table 1. Glange from Dasenne in MAF (ining) Alter 30 Windles Double-Diniu Iniusion (Stud	iy i)

	Treatment					
Endpoint	0.3 μg/kg/min (N = 50)	1 μg/kg/min (N = 49)	2 µg/kg/min (N = 53)	3 μg/kg/min (N = 51)		
Baseline	76 ± 11	77 ± 15	74 ± 12	76 ± 12		
30 Min	65 ± 13	60 ± 15	54 ± 12	60 ± 18		
Change from Baseline	-11 ± 16 (-15, -6.5)	-17 ± 13 (-21, -13)	-20 ± 16 (-24, -16)	-17 ± 19 (-22, -11)		
an ± SD (95% CI)						

INDICATIONS AND USAGE

Sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Concomitant longer-acting antihypertensive medication should be administered so that

the duration of treatment with sodium nitroprusside can be minimized. Sodium nitroprusside is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. Sodium nitroprusside is also indicated for the treatment of acute congestive heart failure

CONTRAINDICATIONS

souaht.

Sodium nitroprusside should not be used in the treatment of compensatory hypertension, where the primary hemodynamic lesion is aortic coarctation or arteriovenous shunting. Sodium nitroprusside should not be used to produce hypotension during surgery in patients with known inadequate cerebral circulation, or in moribund patients (A.S.A. Class 5E) coming to emergency surgery.

Patients with congenital (Leber's) optic atrophy or with tobacco amblyopia have unusually high cyanide/thiocyanate ratios. These rare conditions are probably associated with defective or absent rhodanase, and sodium nitroprusside should be avoided in these patients.

Sodium nitroprusside should not be used for the treatment of acute congestive heart failure associated with

reduced peripheral vascular resistance such as high-output heart failure that may be seen in endotoxic sepsis WARNINGS

(See also the boxed warning at the beginning of this insert.) The principal hazards of NITROPRESS administration are excessive hypotension and excessive accumulation of cyanide (see also **OVERDOSAGE** and **DOSAGE AND ADMINISTRATION**).

or cyanice (see also **OVEROUSACE** and **DUSACE** AND **ADMINISTRATION**). **Excessive Hypotension**: Small transient excesses in the infusion rate of sodium nitroprusside can result in excessive hypotension, sometimes to levels so low as to compromise the perfusion of vital organs. These hemodynamic changes may lead to a variety of associated symptoms; see **ADVERSE REACTIONS**. Nitroprusside-induced hypotension will be self-limited within 1-10 minutes after discontinuation of the Intropresside infusion; during these few minutes, it may be helpful to put the patient into a head-down (Trendelenburg) position to maximize venous return. If hypotension persists more than a few minutes after discontinuation of the infusion of NITROPRESS, NITROPRESS is not the cause, and the true cause must be

matter is visible, should not be used. If properly protected from light, the freshly diluted solution is stable for reactions with trace contaminants. The products of these reactions are often blue, green, or red, much brighter than the faint brownish color of unreacted MITROPRESS. Discolored solutions, or solutions in which particulate should be protected from light, using the supplied opaque sleeve, aluminum foil, or other opaque material. It is not necessary to cover the infusion drip chamber or the tubing. Verification of the chemical integrity of the product: Sodium nitroprusside solution can be inactivated by

Dilution to proper strength for intusion: Depending on the desired concentration, the solution containing 50 mg (ADM) (A NOITAATSINIMDA DNA 3DA2OD

dangerous degree. The nitrite/thiosulfate regimen may be repeated, at half the original doses, after two hours.

solution. I hiosultate treatment of an acutely cyanide-toxic patient will raise thiocyanate levels, but not to a cause transient vasouilatation and hypotension, and this hypotension must, if it occurs, be routinely managed. Immediately after infusion of the sodium mitrite, sodium thiosulfate should be infused. This agent is available in flow and 25% solutions, and the recommended dosa is 150-200 mg/kg; a typical adult dose is 50 mL of the 25%

The domains to increase in the next own can be it wan connacts more a more standard and the increase of the standard and the standard the standard and the standard the standard and the s

The necessary medications for this treatment are contained in commercially available Cyanide Antidote Kits. Alternatively, discrete stocks of medications can be used. Hemodialysis is ineffective in removal of cyanide, but it will eliminate most thiocyanate.

providing a buffer for cyanide by using sodium nitrite to convert as much hemoglobin into methemoglobin as the patient can safely tolerate; and then
 infusing sodium thiosulfate in sufficient quantity to convert the cyanide into thiocyanate.

8.4, and 11.2 mg/kg, respectively mean locas (LDG), or intropristice in fabors, orgs, mice, and racs are z.o, z.o., and 11.2 mg/kg, respectively interpretently interpre

The acute intravenous mean lethal doses (LD₅₀) of nitroprusside in rabbits, dogs, mice, and rats are 2.8, 5.0, be added at 3 and "se accession". Overdosage of introprusside can be manifested as excessive hypotension or cyanide toxicity (see WARNINGS) or as those participations to the **ADVERSE MENTIONS**. The support propriet propriet of the support of the propriet of the support of the sup

39ASOGRAVO

Miscellaneous: Flushing, venous streaking, irritation at the infusion site. Neurologic: Increased intracranial pressure.

Dermatologic: Rash. Endocrine: Hypothyroidism. Gastroinetait lleus. Hematologic: Decreased platelet aggregation.

reappear with a continued (or resumed) slower intrusion. Other adverse reactions reported are: **Cardiovascular:** Bradycardia, electrocardiographic changes, tachycardia. **Gardiovascular:** Brady

This via can be an provide the part of the provide. The thyroid. This via can be an provide the part of the provide the provided the provide the provided the

of the dialyzer.

thiocyanate. Thiocyanate clearance rates during dialysis, on the other hand, can approach the blood flow rate

below 1 mmol/L, a prolonged infusion of sodium nitroprusside should not be more rapid than 3 mcg/kg/min; in nucle patients, the corresponding limit is just 1 mcg/kg/min. When prolonged infusions are more rapid than these, thioryanate levels should be measured daily. Physiologic maneuvers (e.g., those that after the PH of the urine) are not known to increase the elimination of Thicxyanate toxicity is life-threatening when levels are 3 or 4 times higher (200 mg/L). The steady-state thricxyanate level after prolonged infusions of sodium nitroprusside is increased with increased infusion rate, and the half-time of accumulation is 3-4 days. To keep the steady-state thicxyanate level

When meteriorugoundentia is draginose, in the adment of noncer in 2-r ingk, on maturine due, and maturine and summarster intravenously over several minutes. In patients likely to have substantial amounts of cyanide bound to methemoglobin as cyanmethemoglobin, treatment of methemoglobinemia with methylene blue must be undertaken with extreme caution. **Thiocyanate Toxicity:** A described in **CLVIKAL PHARMACOLOGY** above, most of the cyanide produced during accelerated by the co-infusion of thiocuratide is eliminated in the form of thiocyanate. When cyanide elimination is accelerated by the co-infusion of thiocuratie, ninosis, hyperreflexia) at server leaves of 1 mmo/L (60 mg/L). Thiocyanate toxicity neurotoxic (innitus, ninosis, hyperreflexia) at server leaves of the cyanide elimination into the server leaves of the toxic of the cyanide of mould. (60 mg/L).

delivery despite adequate cardiac output and adequate arterial pO2. Classically, methemoglobinemic blood is described as chocolate brown, without color change on exposure to air. When methemoglobinemia is diagnosed, the treatment of choice is 1-2 mg/kg of methylene blue, administered

reach this total accumulated dose. Methemoglobin levels can be measured by most clinical laboratories. The diagnosis should be suspected in patients who have received >10 mg/kg of sodium nitroprusside and who exhibit signs of impaired oxygen

and cyanne dokrony, described above nucle inventions. The adverse reactions described in this section of develop less rapidly and, as it in Appense, less commonly. Methemoglobinemis: As described in CLINICAL PHARMACOLOPY above, sodium nitroprusside infusions can cause sequents of the described in CLINICAL PHARMACOLOPY above, sodium nitroprusside infusions can particulate adverse in the medicina section of hemoglobin amethemoglobin. The back-conversion process is normally the pack. Even pack and the provide the process is normally incapable of back-conversion process in ormality lineapable of back-conversion process in ormality lineapable of back-conversion process. For mathemoglobinemia only after they have received about 10 mg/kg of sodium nitroprusside, and a patient receiving sodium nitroprusside at the maximum recommended rate (10 mg/kg/min) would take over 16 hours to receiving sodium nitroprusside at the maximum recommended rate (10 mg/kg/min) would take over 16 hours to receiving sodium nitroprusside at the maximum recommended rate (11 mg/kg/min) would take over 16 hours to receiving sodium nitroprusside to the socieving sodium nitroprusside to solate to the solate to the solate the solate to the solate t

The most important adverse reactions to sodium nitroprusside are the avoidable ones of excessive hypotension and cyanide toxicity, described above noter (WARWINGS. The adverse reactions described in this section development for rotative and one hoppened percentant and the adverse reactions. SNOITCAAR ASRAVOA

dose-ranging trial (Study 1) and an open label trial of at least 12 hour infusion at a rate that achieved adequate MMP control (Study 2) with pediatric patients on sodium nitroprusside. No novel safety issues were seen in these studies in pediatric patients. See **CLINICAL PHARMACOLOGY** and **DOSAGE AND ADMINISTIRATION**. nursing infants from sodium nitroprusside, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use: Efficacy in the pediatric population was established based on adult trials and supported by the

Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in The effects of administering sodium thiosulfate in pregnancy, either by itself or as a co-infusion with sodium furceprustide, are completely unknown. Nursing Mothers: It is not known whether sodium nitroprusside and its metabolites are excreted in human milk. Because many druns are excreted in human milk and heasure of the notatival for sectors educing equations in

3.9 mcg/kg/min for a total of 3.5 mg/kg over 15 hours prior to delivery of a 4.78 gram stillborn infant without any obvious anomalies. Cyanide levels in the fetal liver were less than 10 mcg/mL. Toxic levels have been reported to be more than 30-40 mcg/mL. The mother demonstrated no cyanide toxicity.

Monterstogenic effects: In three studies in pregnant eves, introprusside was shown to cross the placendal barrier. Fetal cyanide levels were shown to be dose-related to maternal levels of orthoprusside. The metabolic charaformation of 25 mcg/kg/min of sodium nitroprusside for one hour in pregnant eves of cyanide in the fetuses. The intrusion of 25 mcg/kg/min of sodium nitroprusside for one hour in pregnant eves teal related in the death of all fetuses. Pregnant eves intraed with 1 mcg/kg/min of sodium nitroprusside for one hour delivered normal lambs. Cororted gestational hypertension second any to mitral valve disease. Sodium nitroprusside at 3.9 mcc/kg/min to one investigator, a pregnant were at site at second and a so in the death of the cororted gestational hypertension second any to mitral valve disease. Sodium nitroprusside was a forked with any of exercision second any to mitral valve disease. To disting the death of all the death of the studied second avect of the disease. Sodium nitroprusside to the death of the attraction second avect of the disease. Sodium nitroprusside to a precision at hypertension second avect of the disease. Sodium nitroprusside was a forked ware the studied are attracted attracted to the disease.

Dody's red-cell mass has been exhausted.
Drug Interactions: The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive diffect of sodium nitroprusside is augmented by the contropressing sodium nitroprusside's carcinogenesis, Mutagenesis, and Impairment of Fertility.
Carcinogencis, Mutagenesis, and Impairment of Fertility. Animal studies assessing sodium nitroprusside's carcinogenesis, Mutagenesis, and Impairment of Fertility.
Carcinogencipy and mutagenesis, and Impairment of Fertility. Sodium nitroprusside has not been tested to reflects on fertility.
There are no adequate, well-controlled studies of NITROPRESS in either laboratory animals or pregnant women.
There are no adequate, well-controlled studies of NITROPRESS in either laboratory animals or pregnant women.
There are no adequate, well-controlled studies of NITROPRESS and on a diministry.
Solution nitroprusside has not been tested is a pregnant women or can adequate, well-controlled studies of NITROPRESS and the placental administreted to a pregnant women.
There are no adequate, well-controlled studies of NITROPRESS and the placental administry of the capant women.
There are no adequate, well-controlled studies of NITROPRESS and the placental administry of the placental administry pody's red-cell mass has been exhausted.

Laboratory Tests: The cyanide-level assay is technically difficult, and cyanide levels in body fluids other than packed red blood cells are difficult to interpret. Cyanide toxicity will lead to lactic acidosis and venous hyperoxemia, but these findings may not be present until an hour or more after the cyanide capacity of the hode root and are the present antil an hour or more after the cyanide capacity of the proversed are an areas the present antil an hour or more after the cyanide capacity of the hour or more the present and the present until an hour or more after the cyanide capacity of the proversed areas the present and the present antil an hour or more after the cyanide capacity of the proversed areas the present areas the present and the present area after the cyanide capacity of the present areas the present area after the present and the present area after the cyanide capacity of the present areas the present area after the present area after the cyanide to the present area after the present area after the present area after the cyanide to the present area after the present area after the present area after the present area after the cyanide to the present area after the pr

Tepure, condomrand, munistering, many reacting and managed to prove the manual manual manual terministeria. When social manual many teacting and the module disportantion in the manual many teacting and the module disportantion many teacting and the module disportantion of NITROPRES. The possible, the patient's capacity to compensate for anomia and hypowolemia may be diministration of NITROPRES. Hypotensive anesthetic teapscript to compensate for anomia and hypowolemia may be diministration of NITROPRES. Hypotensive anesthetic teapscript to compensate for anomia and hypowolemia and hypowolemia and hypotensis and hypowolemia should be corrected prior to administration of NITROPRES. Hypotensive anesthetic team and hypotensis and hypotensis. The patient's capacity to compensate for anomia and hypotensis and h Hepatic: Use caution when administering nitroprusside to patients with hepatic insufficiency.

vhose intracranial pressure is already elevated, sodium nitroprusside should be used only with extrer General: Like other vasodilators, sodium nitroprusside can cause increases in intracranial pressure. In patients **SNOITUADER**

more sensitive to the effects of sodium nitroprusside than normal subjects.

Reference ID: 3442071

vocardial intarction; ataxia, seizures, and stroke; and other diffuse ischemic damage. Hypertensive patients, and patients concomitantly receiving other antihypertensive medications, may be Cyanide toxicity due to causes other than nitroprusside has been associated with angina pectoris and thiosulfate caused dramatic clinical improvement, supporting the diagnosis of cyanide toxicity. Cyanide toxicity may manifest itself as venous hyperoxemia with bright red venous blood, as cells become unable to exist the oxygen delivered them; merupabolic (lacto) acidosis; air hunger; confusion; and death. as cells become rates for only a few hours and even, in one case, for only 35 minutes. In some of these cases, infusion of sodium deterioration, however, have occasionally been reported in patients who received infusions at recon

administered at 10 mcq/kq/min (the maximum recommended rate). Thereafter, the toxic effects of CN⁻ may be The true rates of clinically important cyanide toxicity cannot be assessed from spontaneous reports or

published data. Most patients reported to have experienced such toxicity have received relatively prolonged infusions, and the only patients whose deaths have been unequivocally attributed to nitroprusside-induced cyanide toxicity have been patients who had received nitroprusside infusions at rates (30-120 mcg/kg/min) much greater than those now recommended. Elevated cyanide levels, metabolic acidosis, and marked clinical

Sugnit Cyanide Toxicity: As described in *CLINICAL PHARMACOLOGY* above, sodium nitroprusside infusions at rates above 2 mcg/kg/min generate cyanide ion (CN⁻) faster than the body can normally dispose of it. (When sodium thiosulfate is given, as described under **DOSAGE AND ADMINISTRATION**, the body's capacity for CN elimination is greatly increased.) Methemoglobin normally present in the body can buffer a certain amount of CN⁻, but the capacity of this system is exhausted by the CN⁻ produced from about 500 mcg/kg of sodium nitroprusside. This amount of sodium nitroprusside is administered in less than an hour when the drug is